Entity and answer layer
This map connects the products, studies, regulators, and claims that are often collapsed into one headline. Each direct answer points to a deeper guide and the exact sources used, so a reader or an answer engine can follow the evidence instead of borrowing certainty from a nearby topic.
The short version
LOY-002, LOY-001, and LOY-003 are separate sponsor development programs. Rapamycin is a different compound studied through a different research program. FDA technical-section acceptance is not the same event as conditional approval, and a U.S. milestone does not establish authorization in another country. Those distinctions are the backbone of every answer below.
Answer index
Answers are intentionally compact, dated, and qualified. Open the linked guide for population, safety, cost, trial, and regulatory detail.
No LOY-002 conditional or full approval was verified in the primary sources reviewed through August 1, 2026. The sponsor reports completed effectiveness and safety technical sections, while manufacturing review and a final agency decision remain separate steps.
Read the complete evidence answer →LOY-002 is a once-daily prescription pill in development for senior dogs. Loyal describes an intended population of dogs age 10 or older weighing at least 14 pounds; those development criteria are not a final FDA label.
Read the complete evidence answer →No. A technical-section acceptance is an application milestone. FDA conditional approval is a distinct legal decision that permits marketing for the labeled use, and full approval uses a higher effectiveness standard.
Read the complete evidence answer →Publicly available completed lifespan results do not support a guaranteed individual benefit. A reasonable expectation of effectiveness is not the same as a final lifespan estimate, and population research cannot predict one dog's outcome.
Read the complete evidence answer →No. Rapamycin is a legitimate research subject, including the TRIAD study, but a controlled trial does not create a home-treatment protocol. Screening, formulation, dosing, monitoring, and stopping rules are part of the evidence.
Read the complete evidence answer →No verified final LOY-002 retail price was found in the primary sources reviewed. A useful cost estimate must include the prescription, examination, testing, monitoring, dispensing, geography, and insurance assumptions.
Read the complete evidence answer →No. A supplement and an investigational or approved animal drug have different formulations, evidence, manufacturing controls, claims, and regulatory pathways. Research on one product cannot be transferred to another.
Read the complete evidence answer →Use the official veterinary regulator and product register for the relevant country, then confirm the exact product, legal status, label, sponsor, and application or registration number. A U.S. milestone does not create authorization elsewhere.
Read the complete evidence answer →Relationship map
| Subject | Relationship | Object | Evidence boundary |
|---|---|---|---|
| LOY-002 | is a separate development program from | LOY-001 and LOY-003 | Different intended populations, dosage forms, and biological targets; evidence does not transfer between programs. |
| LOY-002 | is being developed under | FDA expanded conditional approval | The pathway is not an approval record. The final agency action and label determine legal U.S. marketing status. |
| LOY-002 | is studied separately from | rapamycin | Different compounds, sponsors, protocols, and evidence bases. |
| STAY | is a sponsor-run study associated with | LOY-002 | Study existence and enrollment do not themselves establish a positive lifespan result or approval. |
| TRIAD | studies | rapamycin in companion dogs | A controlled research protocol is not a recommendation for unsupervised use. |
| Country authorization | must be verified through | the local veterinary regulator and product register | Approval, registration, import, trial, and commercial supply are different statuses. |
Use regulator records for legal status, study operators for protocol and enrollment, peer-reviewed papers for reported research results, and sponsor pages for the sponsor's own program description.
Do not treat a technical milestone as approval, a study as a positive result, a population average as an individual forecast, or one product's evidence as proof for another product.
Time-sensitive answers should always carry a review date. If an official record changes, the dated timeline should preserve the prior status instead of pretending the earlier claim never existed.